ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 04/29/2025 at 22:05, 1 year 3 months ago

Abivax annonce la fin du recrutement des patients dans le cadre de ses essais de phase 3 ABTECT dans le traitement de la rectocolite hémorragique (RCH) modérément à sévèrement active
Abivax annonce la fin du recrutement des patients pour les essais de phase 3 ABTECT dans le traitement de la rectocolite hémorragique. Premiers résultats attendus au T3 2025

Abivax Obefazimod Rectocolite Hémorragique Essais De Phase 3 RCH
PRESS RELEASE

published on 04/29/2025 at 22:05, 1 year 3 months ago

Abivax annonce la fin du recrutement des patients dans le cadre de ses essais de phase 3 ABTECT dans le traitement de la rectocolite hémorragique (RCH) modérément à sévèrement active
Abivax annonce la fin du recrutement des patients pour ses essais de phase 3 ABTECT dans le traitement de la rectocolite hémorragique (RCH). Premiers résultats attendus T3 2025

Abivax Rectocolite Hémorragique Phase 3 ABTECT RCH
PRESS RELEASE

published on 04/29/2025 at 22:05, 1 year 3 months ago

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax completes enrollment for Phase 3 ABTECT Trials in patients with active ulcerative colitis. Top-line results expected in Q3 2025, NDA submission planned for H2 2026

Abivax Ulcerative Colitis Phase 3 ABTECT Trials NDA Submission
BRIEF

published on 04/22/2025 at 22:10, 1 year 3 months ago

Abivax : Modalités de l'Assemblée Générale Annuelle et perspectives 2025

Investissement Biotechnologie Abivax Essais Cliniques Assemblée Générale 2025
BRIEF

published on 04/22/2025 at 22:10, 1 year 3 months ago

Abivax: Terms of the Annual General Meeting and outlook for 2025

Biotechnology Abivax Clinical Trials Investment General Meeting 2025
PRESS RELEASE

published on 04/22/2025 at 22:05, 1 year 3 months ago

Abivax annonce les modalités de son Assemblée Générale Annuelle alors que la Société se rapproche d’étapes clés créatrices de valeur en 2025
Abivax annonce les modalités de son Assemblée Générale Annuelle pour le 6 juin 2025 à Paris, alors que la Société se rapproche d'étapes clés en 2025

Biotechnologie Abivax Assemblée Générale Annuelle Phase 3 Mécanismes De Régulation
PRESS RELEASE

published on 04/22/2025 at 22:05, 1 year 3 months ago

Abivax annonce les modalités de son Assemblée Générale Annuelle alors que la Société se rapproche d’étapes clés créatrices de valeur en 2025
Abivax annonce les modalités de son Assemblée Générale Annuelle et se rapproche d'étapes clés créatrices de valeur en 2025. Essais cliniques ABTECT de phase 3 en progression

Abivax Étapes Clés Assemblée Générale Annuelle Phase 3 ABTECT
BRIEF

published on 04/22/2025 at 22:05, 1 year 3 months ago

Abivax accueille le Dr Dominik Höchli au sein de son Conseil d’administration

Abivax Conseil D'administration Phase 3 Immunologie Dominik Höchli
BRIEF

published on 04/22/2025 at 22:05, 1 year 3 months ago

Abivax welcomes Dr. Dominik Höchli to its Board of Directors

Board Of Directors Abivax Phase 3 Immunology Dominik Höchli
PRESS RELEASE

published on 04/22/2025 at 22:05, 1 year 3 months ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Abivax announces details of Annual General Meeting on June 6, 2025, in Paris as it progresses towards key 2025 milestones, including Phase 3 ABTECT trials

Annual General Meeting Abivax Clinical-stage Biotechnology Phase 3 ABTECT Trials 2025 Milestones

Published on 08/07/2026 at 14:17, 56 minutes ago

NuRAN Wireless Increases Series A Preferred Share Financing to C$7.6 Million and Announces Debt Settlements
Published on 08/07/2026 at 13:00, 2 hours 13 minutes ago

Gold Terra Announces Start of Drilling on the Campbell Shear Northern Zone 103N Extension to Expand 2026 MRE of Inferred 595,000 Ounces, Con Mine, Yellowknife, NWT
Published on 08/07/2026 at 00:45, 14 hours 28 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 15 hours 58 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 16 hours 58 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

View all ACCESSWIRE

Published on 08/07/2026 at 15:06, 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/07/2026 at 15:05, 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 08/07/2026 at 15:04, 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/07/2026 at 15:03, 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 08/07/2026 at 15:02, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: easyJet plc

View all EQS

Published on 08/07/2026 at 08:30, 6 hours 43 minutes ago

Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/07/2026 at 08:30, 6 hours 43 minutes ago

Déclaration nombre d'actions et droits de vote - 07.08.2026
Published on 08/06/2026 at 18:26, 20 hours 47 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 20 hours 47 minutes ago

Air Liquide droits de vote au 31 juillet 2026
Published on 08/06/2026 at 17:46, 21 hours 27 minutes ago

Déclaration des droits de vote à fin juillet 2026

View all LES ECHOS COMFI WIRE

News